EurekAlert! -
19 Mar 2017 06:00
(American College of Cardiology) When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly reduce rates of death, heart attack, kidney dialysis or use of a mechanical assist device among patients at high risk for low cardiac output syndrome, according to a study presented at the American College of Cardiology's 66th Annual Scientific Session.
Share this Article